Protagenic Therapeutics (PTIX) — Strategic Asset Allocation Index
Protagenic Therapeutics (PTIX) has a Strategic Asset Allocation Index of 0.2% as of September 2018. Strategic assets (PP&E of $732.00 plus long-term investments of $0.00) total $732.00, measured against net assets of $323.03K. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of Protagenic Therapeutics to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Protagenic Therapeutics Strategic Asset Allocation Index (2016–2017)
This chart shows how Protagenic Therapeutics's Strategic Asset Allocation Index has evolved across 2 annual periods from 2016 to 2017. As of September 2018, the index stands at 0.2%, representing strategic assets of $732.00 against net assets of $323.03K USD. For live market cap and overall valuation, see PTIX stock market capitalisation.
Annual Strategic Asset Allocation Index for Protagenic Therapeutics (2016–2017)
The table below presents the year-by-year Strategic Asset Allocation Index for Protagenic Therapeutics from 2016 to 2017, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See PTIX net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2017 | 0.1% | $1.02K | $1.02K | $0.00 | $1.22 Million | ▲ +0.0 pp |
| 2016 | 0.0% | $1.10K | $1.10K | $0.00 | $2.48 Million | — |